Skip to main content
Drug Design, Development and Therapy logoLink to Drug Design, Development and Therapy
. 2014 Mar 20;8:325. doi: 10.2147/DDDT.S63655

Daclatasvir: potential role in hepatitis C [Corrigendum]

PMCID: PMC3964031

Lee C. Drug Des Devel Ther. 2013;7:1223–1233.

On page 1231 in the “Conclusion” section, line 3 contains incorrect information. The correct sentence is “This review summarizes key preclinical and clinical data of an HCV NS5A inhibitor, DCV, describing its discovery, mechanism of action, resistance profile, in vitro and in vivo efficacy and toxicity, and polymorphism.”


Articles from Drug Design, Development and Therapy are provided here courtesy of Dove Press

RESOURCES